Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      GSK gets USFDA nod for HIV-1 drug branded as Dovato

      GSK gets USFDA nod for HIV-1 drug branded as Dovato

      Farhat Nasim9 April 2019 9:20 AM IST
      GSK already has two-drug regimen Juluca on the market, but only for the smaller market of HIV patients that have received prior treatment. Dovato is...
      Defeat Cancer, Both Physically and Financially

      Defeat Cancer, Both Physically and Financially

      Farhat Nasim9 April 2019 8:59 AM IST
      New Delhi: Here are some facts about cancer and its spread in India: According to the National Institute for Cancer Prevention and Research (NICPR),...
      Zydus Cadila gets tentative USFDA nod to Lacosamide tablets to treat seizures

      Zydus Cadila gets tentative USFDA nod to Lacosamide tablets to treat seizures

      Farhat Nasim8 April 2019 10:00 AM IST
      Lacosamide is an anti convulsant or anti-epileptic drug, used to prevent and control seizures. It works by reducing the spread of seizure activity in...
      Lupin recalls over 12000 cartons of Fayosim from US market

      Lupin recalls over 12000 cartons of Fayosim from US market

      Farhat Nasim8 April 2019 9:30 AM IST
      New Delhi: Drug firm Lupin is recalling over 12,000 cartons of Fayosim tablets, used to prevent pregnancy, from the American market, as per a report...
      Pfizer, GSK consumer healthcare venture to focus on China, US market

      Pfizer, GSK consumer healthcare venture to focus on China, US market

      Farhat Nasim7 April 2019 9:14 AM IST
      LONDON: The United States and China will be key focuses for the consumer healthcare venture being formed by GlaxoSmithKline and Pfizer, as the...
      Zydus Cadila gets tentative USFDA nod to Tofacitinib tablets for treating arthritis

      Zydus Cadila gets tentative USFDA nod to Tofacitinib tablets for treating arthritis

      Farhat Nasim6 April 2019 3:00 PM IST
      Tofacitinib is used alone or with other medications to treat moderate to severe forms of rheumatoid arthritis, the company said in a BSE filing. New...
      Pfizer gets EU nod to VIZIMPRO for treating lung cancer

      Pfizer gets EU nod to VIZIMPRO for treating lung cancer

      Farhat Nasim6 April 2019 9:40 AM IST
      New Delhi: Pfizer Inc. recently announced that the European Commission has approved VIZIMPRO (dacomitinib), a tyrosine kinase inhibitor (TKI), as...
      Novartis, Amgen in dispute over Aimovig partnership

      Novartis, Amgen in dispute over Aimovig partnership

      Farhat Nasim6 April 2019 9:30 AM IST
      NEW YORK: Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of...
      Goa facility receives EIR from USFDA: Cipla

      Goa facility receives EIR from USFDA: Cipla

      Farhat Nasim5 April 2019 9:36 AM IST
      New Delhi: Pharma major Cipla Thursday said it has received an establishment inspection report(EIR) from the US health regulator after inspection of...
      Pfizer wins USFDA approval for IBRANCE to treat men with Metastatic Breast Cancer

      Pfizer wins USFDA approval for IBRANCE to treat men with Metastatic Breast Cancer

      Farhat Nasim5 April 2019 9:35 AM IST
      New Delhi: Drug maker, Pfizer recently announced that the U.S. Food and Drug Administration (USFDA) has approved a supplemental New Drug Application...
      USFDA completes inspection of Lupin Bioresearch Centre Pune

      USFDA completes inspection of Lupin Bioresearch Centre Pune

      Farhat Nasim5 April 2019 9:30 AM IST
      The inspection of Lupin Bioresearch Centre by the United States Food and Drug Administration (USFDA) has been successfully completed without any...
      Emcure launches generic Eribulin at 40 percent lower price in India

      Emcure launches generic Eribulin at 40 percent lower price in India

      Farhat Nasim4 April 2019 9:30 AM IST
      Emcure Pharmaceuticals will manufacture Eribulin at its plant at Hinjewadi in Pune and market it at a cost which will be approximately 40 per cent...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok